
CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising an anti-CD79b immunoconjugate and a surfactant, wherein the surfactant is at a concentration of at least 0.06% w/v, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from about 1 to about 8.

2. The pharmaceutical composition of claim 1, wherein the anti-CD79b immunoconjugate is at a concentration of about 5 mg/ml to about 60 mg/ml, about 10 mg/ml to about 50 mg/ml, about 10 mg/ml to about 40 mg/ml, about 10 mg/ml to about 30 mg/ml, or about 10 mg/ml to about 20 mg/ml.

3. The pharmaceutical composition of claim 2, wherein the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml to about 20 mg/ml.

4. The pharmaceutical composition of claim 2 or 3, wherein the anti-CD79b immunoconjugate is at a concentration of 20 mg/ml.

5. The pharmaceutical composition of any one of claims 1-3, wherein the composition comprises the anti-CD79b immunoconjugate at a concentration of 10 mg/ml and the surfactant at a concentration of 0.06% w/v.

6. The pharmaceutical composition of any one of claims 1-4, wherein the composition comprises the anti-CD79b immunoconjugate at a concentration of 20 mg/ml and the surfactant at a concentration of 0.12% w/v.

7. The pharmaceutical composition of any one of claims 1-4, wherein the composition comprises the anti-CD79b immunoconjugate at a concentration of 20 mg/ml and the surfactant at a concentration of at least 0.12% w/v.

8. The pharmaceutical composition of any one of claims 1-7, wherein the surfactant is selected from the group consisting of: polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188 (P188), N-octyl-β-D glucopyranoside (OG), and a combination thereof.

9. The pharmaceutical composition of any one of claims 1-8, wherein the composition further comprises a buffering agent.

10. The pharmaceutical composition of claim 9, wherein the buffering agent is a histidine buffer or a succinate buffer.

11. The pharmaceutical composition of claim 10, wherein the buffering agent is a histidine buffer.

12. The pharmaceutical composition of claim 10, wherein the buffering agent is a succinate buffer.

13. The composition of claim 12, wherein the succinate buffer is a sodium succinate buffer.

14. The pharmaceutical composition of claim 13, wherein the sodium succinate buffer is at a concentration of about 10 mM to about 200 mM.

15. The pharmaceutical composition of claim 14, wherein the sodium succinate buffer is at a concentration of 10 mM.

16. The pharmaceutical composition of any one of claims 1-15, wherein the composition has a pH of about 5.0 to about 6.0.

17. The pharmaceutical composition of claim 16, wherein the composition has a pH of 5.3.

18. The pharmaceutical composition of any one of claims 1-17, wherein the composition further comprises a sugar.

19. The pharmaceutical composition of claim 18, wherein the sugar is at a concentration of about 100 mM to about 260 mM.


20. The pharmaceutical composition of claims 18-19, wherein the sugar is selected from the group consisting of: sucrose, mannitol, sorbitol, glycerol, dextran 40, and trehalose.

21. The pharmaceutical composition of claim 20, wherein the sugar is sucrose.

22. The pharmaceutical composition of claim 22, wherein the sucrose is at a concentration of 120 mM.

23. The pharmaceutical composition of any one of claims 1-22, wherein the composition has been reconstituted from a lyophilized cake.

24. A pharmaceutical composition produced by lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid compostion has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and


p is a value from about 1 to about 8.

25. The pharmaceutical composition of any one of claims 1-24, wherein the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.

26. The pharmaceutical composition of any one of claims 1-25, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9 and the light chain comprises the amino acid sequence of SEQ ID NO: 10.

27. The pharmaceutical composition of any one of claims 1-26, wherein p is a value between about 2 and about 5.

28. A pharmaceutical composition produced by lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, the light chain comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5.

29. The pharmaceutical composition of any one of claims 1-28, wherein p is about 3.5.

30. The pharmaceutical composition of any one of claims 24-29, wherein the composition has a stability of about 48 months at 5°C ± 3°C when protected from light.

31. The pharmaceutical composition of claim 30, wherein the stability of the composition is measured by size-exclusion high performance liquid chromatography (SE-HPLC).

32. The pharmaceutical composition of claim 31, wherein the composition has a main peak (area %) of at least 95.0 as measured by SE-HPLC.

33. The pharmaceutical composition of claim any one of claims 28-32, wherein the stability of the composition is measured by imaged capillary isoelectric focusing (icIEF).

34. The pharmaceutical composition of claim 33, wherein the composition has a main peak (area %) of at least 58.0, an acid region (area %) of at most 32.0, and a basic region (area %) of at most 12.0 as measured by icIEF.

35. The pharmaceutical composition of any one of claims 24-34, wherein the pharmaceutical composition is a lyophilized cake.

36. The pharmaceutical composition of any one of claims 1-35, wherein the pharmaceutical composition is reconstituted with sterile water for injection (SWFI) to produce a reconstituted composition.

37. The pharmaceutical composition of any one of claims 1-35, wherein the pharmaceutical composition is reconstituted in about 7.2 ml SWFI to produce a reconstituted composition.

38. The pharmaceutical composition of claim 36 or 37, wherein the reconstituted composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C.

39. The pharmaceutical composition of any one of claims 36-38, wherein the reconstituted composition is stable for at least 24, 48, or 72 hours upon storage at about 2°C to about 8°C.


40. The pharmaceutical composition of any one of claims 36-39, wherein the reconstituted composition can be further diluted into an isotonic buffer in an intravenous (IV) bag to produce a diluted composition.

41. The pharmaceutical composition of claim 40, wherein the final volume of the diluted composition in the IV bag is about 100 ml.

42. The pharmaceutical composition of claim 40 or 41, wherein the concentration of the immunoconjugate in the diluted composition is between about 0.72 mg/ml and about 2.7 mg/ml.

43. A pharmaceutical composition produced by a process comprising the steps of:

(a) lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, the light chain comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5, to produce a lyophilized composition;

(b) reconstituting the lyophilized composition with about 7.2 ml sterile water for injection (SWFI) to produce a reconstituted composition; and

(c) diluting the reconstituted composition into an isotonic buffer in an intravenous (IV) bag to produce the pharmaceutical composition,

wherein the final volume of the pharmaceutical composition in the IV bag is about 100 ml, and

wherein the final concentration of the immunoconjugate in the pharmaceutical composition is about 0.72 mg/ml or about 2.7 mg/ml.

44. The pharmaceutical composition of claim 43, wherein p is about 3.5.

45. The pharmaceutical composition of any one of claims 38-44, wherein the isotonic buffer is an 0.9% sodium chloride solution, an 0.45% sodium chloride solution, or a 5% dextrose solution.

46. A liquid composition comprising a) between about 0.72-2.7 mg/ml polatuzumab vedotin; b) between about 0.36 -0 1.35 mM sodium succinate; c) between about 0.51-16.24 mM sucrose; d) betweetn about 0.0432 -0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5 and about 5.7.

47. A liquid composition comprising a) about 0.72 mg/ml polatuzumab vedotin; b) about 0.36 mM sodium succinate; c) about 0.51 mM sucrose; d) about 0.0432 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5.1 and about 5.4.


48. A liquid composition comprising a) about 2.7 mg/ml polatuzumab vedotin; b) about 0 1.35 mM sodium succinate; c) about 16.24 mM sucrose; d) about 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5.1 and about 5.4.

49. The liquid composition of any one of claims 46-48, wherein the volume of the liquid composition is between about 50 ml and about 100 ml.

50. The liquid composition of claim 49, wherein the volume of the liquid composition is 50 ml.

51. The liquid composition of claim 49, wherein the volume of the liquid composition is 100 ml.

52. A pharmaceutical composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the pharmaceutical composition, when reconstituted in water, forms a liquid pharmaceutical compostion comprising the anti-CD79b immunoconjugate at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant at a concentration of at least 0.06% w/v, the succinate buffer at a concentration of about 10 mM to about 200 mM, and the sugar at a concentration of about 100 mM to about 260 mM, wherein the liquid pharmaceutical composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from about 1 to about 8.

53. The pharmaceutical composition of claim 52, wherein the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.

54. The pharmaceutical composition of claim 52 or 53, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10.

55. The pharmaceutical composition of any one of claims 24-34 or 52-54 wherein the pharmaceutical composition is produced by lyophilization, and wherein the lyophilized pharmaceutical composition is stable for at least 6, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months upon storage at about 2°C to about 8°C.

56. The pharmaceutical composition of claim 55, wherein the lyophilized pharmaceutical composition is a lyophilized cake.

57. The pharmaceutical composition any one of claims 52-56 wherein the pharmaceutical composition, following reconstitution, is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C.

58. The pharmaceutical composition of any one of claims 52-57, wherein the pharmaceutical composition, following reconstitution, is stable for at least 24, 48, or 72 hours upon storage at about 2°C to about 8°C.

59. The pharmaceutical composition of any one of claims 52-58, wherein the pharmaceutical composition, following reconstitution, is diluted into an isotonic buffer in an IV bag, wherein the surfactant concentration upon dilution in the IV bag is at least 0.003% w/v.

60. The pharmaceutical composition of claim 59, wherein the surfactant concentration upon dilution in the IV bag is at least 0.004% w/v.

61. The pharmaceutical composition of any one of claims 52-60, wherein the surfactant is polysorbate 20.

62. The pharmaceutical composition of any one of claims 52-61, wherein the sugar is sucrose.

63. The pharmaceutical composition of anyone of claims 52-58 and 61-62, wherein the sucrose is at a concentration of 120 mM.

64. The pharmaceutical composition of any one of claims 52-63, wherein the succinate buffer is a sodium succinate buffer.

65. The pharmaceutical composition of claim 64, wherein, following reconstitution but before dilution, the sodium succinate buffer is at a concentration of 10 mM.

66. The pharmaceutical composition of any one of claims 52-58 and 61-65, wherein the composition has a stability of about 7 days at 5°C ± 3°C.

67. The pharmaceutical composition of claim 66, wherein the stability of the composition is measured by size-exclusion high performance liquid chromatography (SE-HPLC).


68. The pharmaceutical composition of claim 67, wherein the composition has a main peak (area %) of at least 95.0 as measured by SE-HPLC.

69. The pharmaceutical composition of any one of claims 52-68, wherein the stability of the composition is measured by imaged capillary isoelectric focusing (icIEF).

70. The pharmaceutical composition of claim 69, wherein the composition has a main peak (area %) of at least 58.0, an acid region (area %) of at most 32.0, and a basic region (area %) of at most 12.0 as measured by icIEF.

71. A glass vial containing the pharmaceutical composition of any one of claims 52-58 and 61-70.

72. A liquid composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant is at a concentration of at least 0.06% w/v, the succinate buffer is at a concentration of about 10 mM to about 200 mM, and the sugar is at a concentration of about 100 mM to about 260 mM, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from about 1 to about 8.

73. The liquid composition of claim 72, wherein the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.

74. The liquid composition of claim 72 or 73, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10.

75. The liquid composition of claim any one of claims 72-74, wherein the surfactant is polysorbate 20.

76. The liquid composition of any one of claims 72-75, wherein the sugar is sucrose.

77. The liquid composition of claim 76, wherein the sucrose is at a concentration of about 120 mM.

78. The liquid composition of any one of claims 72-77, wherein the succinate buffer is a sodium succinate buffer.

79. The liquid composition of claim 78, wherein the sodium succinate buffer is at a concentration of 10 mM.

80. The liquid composition of any one of claims 72-79, wherein the composition is diluted in an isotonic buffer.

81. The liquid composition of claim 80, wherein the isotonic buffer is an 0.9% sodium chloride solution, an 0.45% sodium chloride solution, or a 5% dextrose solution.

82. The liquid composition of claim 80 or 81, wherein the composition that is diluted in an isotonic buffer is in an IV bag.


83. The liquid composition of any one of claims 72-79, wherein the composition has a stability of about 72 hours at 5°C ± 3°C.

84. The liquid composition of any one of claims 72-79, wherein the composition has a stability of about 24 hours at 25°C.

85. The liquid composition of any one of claims 72-79, wherein the liquid composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C.

86. The liquid composition of any one of claims 72-79, wherein the liquid composition is stable for at least 24, 48, or 72 hours upon storage at about 2°C to about 8°C.

87. A lyophilized pharmaceutical composition comprising about 150 mg of an anti-CD79b immunoconjugate, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:




wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and

p is a value from about 2 to about 5.

88. A lyophilized pharmaceutical composition comprising about 150 mg of polatuzumab vedotin, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose.

89. A lyophilized pharmaceutical composition comprising about 140 mg of an anti-CD79b immunoconjugate, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:




wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and

p is a value from about 2 to about 5.

90. A lyophilized pharmaceutical composition comprising about 140 mg of polatuzumab vedotin, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose.

91. A lyophilized pharmaceutical composition comprising about 30 mg of an anti-CD79b immunoconjugate, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5.

92. A lyophilized pharmaceutical composition comprising about 30 mg of polatuzumab vedotin, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose.

93. The lyophilized composition of any one of claims 87, 89, or 91, wherein p is about 3.5.

94. A lyophilized pharmaceutical composition comprising about 140-150 mg of polatuzumab vedotin, about 8.4-9.0 mg polysorbate 20, about 8.27-8.88 mg succinic acid, about 3.80-4.08 mg sodium hydroxide, and about 288-309 mg sucrose.

95. The lyophilized pharmaceutical composition of any one of claims 87-94 wherein the lyophilized pharmaceutical composition is stable for at least 6, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months upon storage at about 2°C to about 8°C.

96. The lyophilized pharmaceutical composition of any one of claims 87-95, wherein the lyophilized pharmaceutical composition is a lyophilized cake.

97. A liquid pharmaceutical composition comprising a) 5-60 mg/ml polatuzumab vedotin; b) 10-200 mM sodium succinate; c) 100-260 mM sucrose; d) 0.06-0.12% w/v polysorbate 20, wherein the pH of the liquid composition is between 5 and 6.

98. The liquid composition of claim 97, comprising a) 10-55 mg/ml polatuzumab vedotin; b) 10-100 mM sodium succinate; c) 150-260 mM sucrose; d) 0.08-0.12% w/v polysorbate 20, wherein the pH of the liquid composition is between 5.1 and 5.6.

99. The liquid composition of claim 97, comprising a) 15-40 mg/ml polatuzumab vedotin; b) 10-50 mM sodium succinate; c) 200-260 mM sucrose; d) 0.1-0.12% w/v polysorbate 20, wherein the pH of the liquid composition is between 5.2 and 5.4.

100. A liquid pharmaceutical composition comprising a) 20 mg/ml polatuzumab vedotin; b) 10 mM sodium succinate; c) 120 mM sucrose; d) 0.12% w/v polysorbate 20, wherein the pH of the liquid composition is about 5.3.

101. The liquid composition of any one of claims 97-100, wherein the liquid composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C.

101. The liquid composition of any one of claims 97-101, wherein the liquid composition is stable for at least 24, 48, or 72 hours upon storage at about 2°C to about 8°C.

102. A method of treating a proliferative disorder in a patient in need thereof comprising administering to the patient the pharmaceutical composition or the liquid composition of any one of the preceding claims.

103. The method of claim 102, wherein the proliferative disorder is cancer.

104. The method of claim 103, wherein the cancer is a B cell proliferative disorder.

105. The method of claim 104, wherein the B cell proliferative disorder is selected from the group consisting of: lymphoma, myeloma, non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), aggressive NHL, indolent lymphoma, follicular lymphoma (FL), relapsed aggressive NHL, relapsed indolent NHL, relapsed NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma.

106. The method of claim 105, wherein the B cell proliferative disorder is non-Hodgkin's lymphoma (NHL).

107. The method of claim 105, wherein the B cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL).

108. The method of claim 105, wherein the B cell proliferative disorder is relapsed NHL or refractory NHL.

109. The method of claim 105, wherein the B cell proliferative disorder is follicular lymphoma (FL).